<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02870218</url>
  </required_header>
  <id_info>
    <org_study_id>201602820</org_study_id>
    <secondary_id>GRANT12052089</secondary_id>
    <nct_id>NCT02870218</nct_id>
  </id_info>
  <brief_title>Abuse Liability of Reduced Nicotine Content Cigarettes in the Context of Concurrent E-Cigarette Use</brief_title>
  <acronym>DUAL</acronym>
  <official_title>Abuse Liability of Reduced Nicotine Content Cigarettes in the Context of Concurrent E-Cigarette Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rose Research Center, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Rose Research Center, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Three hundred-twenty (320) adult smokers of menthol or non-menthol combustible cigarettes
      will be recruited and randomly assigned to one of five groups (n=64/group), who will be asked
      to switch for 12 weeks to ad libitum use of combustible cigarettes (matched to subjects'
      menthol preference) containing either 0.4, 1.4, 2.5, 5.6 or 16.9 mg nicotine (standardized
      nicotine yields ranging from 0.02-0.80 mg/cigarette), respectively. Each group will include
      32 heavy, long-time smokers (≥ 10 cigarettes/day for ≥ 10 years), and 32 light smokers with a
      shorter smoking history (&lt;10 cigarettes/day for &lt;10 years), who are hypothesized to be more
      sensitive to nicotine's reinforcing effects. Participants will also have free access to
      nicotine-containing e-cigarettes (15 mg/ml) throughout the 12-week period. Abuse liability of
      combustible cigarettes will be assessed by behavioral (cigarettes/day, time to first
      cigarettes), self-report (rewarding effects, withdrawal symptoms) and biochemical indices
      (expired air carbon monoxide, cotinine blood sampling).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean number of research cigarettes smoked per day as primary index of abuse liability</measure>
    <time_frame>12 Weeks</time_frame>
    <description>To assess the effects of cigarette nicotine content on abuse liability among smokers who also use e-cigarettes. The primary index of abuse liability will be mean number of research cigarettes smoked per day. Secondary outcome measures comprise expired air carbon monoxide (CO), Fagerström Test for Nicotine Dependence (FTND) score, withdrawal symptoms and cognitive performance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nicotine discrimination tests to determine detection, recognition and difference thresholds</measure>
    <time_frame>Wks 1, 2,8,10,12 and 14</time_frame>
    <description>Results of the laboratory discrimination tests will be analyzed descriptively to determine detection, recognition and difference thresholds. Thresholds will be calculated based on both group-averaged data as well as by using the best estimates of individual thresholds calculated from each smoker's data. Group averaged data will be determined by graphically plotting the overall percent correct against nicotine concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of e-cigarette use based on self-report and cotinine levels</measure>
    <time_frame>12 Weeks</time_frame>
    <description>To determine whether the abuse liability of combustible cigarettes is related to the nicotine intake from e-cigarettes or to total nicotine intake, regression analyses will be conducted to correlate indices of abuse liability to levels of cotinine as well as to the estimated intake of nicotine from cigarettes and e-cigarettes.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Nicotine Addiction</condition>
  <condition>Cigarette Smoking</condition>
  <arm_group>
    <arm_group_label>0.40mg Nicotine Cigarette w/ e-Cigarette</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be assigned to smoke 0.40mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to 15mg/ml nicotine-containing e-cigarettes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.40mg Nicotine Cigarette w/ e-Cigarette</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be assigned to smoke 1.40mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to 15mg/ml nicotine-containing e-cigarettes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.50mg Nicotine Cigarette w/ e-Cigarette</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be assigned to smoke 2.50mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to 15mg/ml nicotine-containing e-cigarettes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5.60mg Nicotine Cigarette w/ e-Cigarette</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be assigned to smoke 5.60mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to 15mg/ml nicotine-containing e-cigarettes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>16.9mg Nicotine Cigarette w/ e-Cigarette</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be assigned to smoke 16.9mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to 15mg/ml nicotine-containing e-cigarettes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Smoking research cigarettes with e-cigarette</intervention_name>
    <description>Smoking research cigarettes with varying levels of nicotine with unlimited access to 15 mg/ml nicotine-containing e-cigarettes.</description>
    <arm_group_label>0.40mg Nicotine Cigarette w/ e-Cigarette</arm_group_label>
    <arm_group_label>1.40mg Nicotine Cigarette w/ e-Cigarette</arm_group_label>
    <arm_group_label>2.50mg Nicotine Cigarette w/ e-Cigarette</arm_group_label>
    <arm_group_label>5.60mg Nicotine Cigarette w/ e-Cigarette</arm_group_label>
    <arm_group_label>16.9mg Nicotine Cigarette w/ e-Cigarette</arm_group_label>
    <other_name>Spectrum Cigarettes</other_name>
    <other_name>NJOY e-Cigarette</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is healthy as judged by the Investigator based on all available assessments
             from the Screening Period (e.g., safety laboratory, vital signs, physical examination,
             ECG, concomitant medications and medical history).

          2. Subject smokes on average four days a week for the last 12 months.

          3. Subject has no intention of quitting smoking within the next 90 days.

          4. Owns a smart phone with text message and data capabilities.

          5. Willingness to use and ability to operate e-cigarettes.

          6. Willingness to smoke Research Cigarettes.

        Exclusion Criteria:

          1. Any medical or psychiatric condition (or associated symptoms or medications)
             determined by a medical professional to be severe enough to be disruptive to the
             study.

          2. Severe or uncontrolled psychiatric disease with the exception of anxiety disorders,
             obsessive-compulsive disorder (OCD) and attention deficit hyperactivity disorder
             (ADHD);

          3. Pregnant or nursing (by self-report) or positive pregnancy test;

          4. Daily use of:

               1. Experimental (investigational) drugs that are unknown to subject;

               2. Smokeless tobacco (chewing tobacco, snuff), cigars, pipes and hookah;

               3. e-cigarettes;

          5. Use in the past 30 days of nicotine replacement therapy or other smoking cessation
             product

          6. Positive drug screen for cocaine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jed E Rose, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rose Research Center, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tanaia Loeback</last_name>
    <phone>9193282345</phone>
    <email>tanaia.loeback@roseresearchcenter.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Botts</last_name>
    <phone>9193282345</phone>
    <email>david.botts@roseresearchcenter.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rose Research Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Derek Mercedes</last_name>
      <phone>704-350-2999</phone>
      <email>derek.mercedes@roseresearchcenter.com</email>
    </contact>
    <investigator>
      <last_name>Jed E Rose, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Davis, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rose Research Center</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27617</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tanaia H Loeback</last_name>
      <email>tanaia.loeback@roseresearchcenter.com</email>
    </contact>
    <contact_backup>
      <last_name>David Botts</last_name>
      <email>david.botts@roseresearchcener.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jed E Rose, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Perry Willette, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Davis, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2016</study_first_submitted>
  <study_first_submitted_qc>August 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2016</study_first_posted>
  <last_update_submitted>September 28, 2017</last_update_submitted>
  <last_update_submitted_qc>September 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rose Research Center, LLC</investigator_affiliation>
    <investigator_full_name>Jed Rose</investigator_full_name>
    <investigator_title>President and CEO</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

